HOOKIPA Pharma Inc. announced the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023. Dr. Schlienger has been promoted to Chief Medical Officer. She has served as the Company's Executive Vice President, Clinical Research and Development since July 2022.

Prior to that, Dr. Schlienger served as Senior Vice President, Head of Immuno-Oncology Clinical Research and Development from January 2021 to June 2022. She previously worked at Merck & Co., for 14 years, serving in roles of increasing responsibility across early and late-stage clinical development in oncology and vaccines. She received an M.D. from the School of Medicine Lariboisiere Saint-Louis in Paris, France and a Ph.D. in Microbiology/Virology from Paris Diderot University.

Dr. Peters serves as Chief Research and Development Officer at MorphoSys and will retire from the company at the end of 2022. He joined MorphoSys in 2017 as Chief Development Officer. In these roles, he oversaw the company's research and development pipeline, including the design and execution of three pivotal studies.

Prior to joining MorpoSys, Dr. Peters was Global Head of Clinical Development of the biopharmaceuticals business unit of Sandoz in Germany. Dr. Peters also spent 12 years in leadership positions at Novartis Oncology, including Vice President, Clinical Head and Site Head for Basel, East Hanover and Shanghai. He was responsible for multiple development programs and clinical trials at Novartis, contributing to the approval of several cancer therapies.

Earlier in his career, he held positions at Micromet AG and Merck KgaA, and also served as a research scientist in infectious disease.